Mouse Anti-NOTCH1 Recombinant Antibody (clone 2E6) (CAT#: NS-060CN)

Figure 1 A histogram summarizing results of an experiment to determine specificity of antibody binding to human Notch 1 on the surface of CHO-Flpln-Notchl cells.

Antibodies 2G10, 2E6 (also referred to herein as antibody 2E06), 2A11, and 2D11 are shown from left to right.

Figure 2 A histogram summarizing results from a Notch 1-specific reporter assay showing that antibody 2E6 (also referred to herein as antibody 2E06) inhibits Notch 1-dependent reporter gene expression in the presence of Jagl.

The Notch 1-specific (Nl-specific) control inhibitor is an anti-Notchl polyclonal antibody. The Notch2-specific (N2-specific) control inhibitor is an anti-Notch2 polyclonal antibody. The Notch3-specific (N3-specific) control inhibitor is an anti-Notch3 polyclonal antibody.

Figure 3 A histogram summarizing results of Notch 1-specific reporter assays showing that antibody 2E6 inhibits Notch 1-dependent reporter gene expression induced by the ligands Jagl, Jag2, DLL1 and DLL4.

Reporter activity in the absence of any activating ligand (Fc + mlgG) was defined as 100% inhibition, and activity in the presence of ligand and treated with mouse IgG (Ligand alone + mlgG) was defined as 0% inhibition.

Figure 4 A histogram showing the effect of DBZ (dibenzazipine; a gamma secretase inhibitor dosed at 10 mMol/kg once daily) and antibody 2E6 (dosed at 40, 100, or 150 mg/kg (abbreviated "mpk") three times per week) on thymocyte population in mice.

Figure 5 A graph showing mouse body weight over time, for mice treated with DBZ or antibody 2E6.

This shows that DBZ at 30 mMol/kg (A) or 10 mMol/kg (■) induces weight loss in mice in 4 days and 17 days, respectively. By contrast, 40 mg/kg (abbreviated as mpk) (*), 100 mg/kg (·), or 150 mg/kg (+) of antibody 2E6 does not induce weight loss in mice (vehicle, (♦) and murine IgG (x)).

Figure 6 A histogram summarizing data from an experiment to assess the effects of antibody 2E6 on functional angiogenesis in vivo induced by bFGF, with hemoglobin content serving as a surrogate indicator of functional angiogenesis.

Figure 7 A histogram summarizing data from an experiment to assess the effects of antibody 2E6 on functional angiogenesis in vivo induced by human cancer cell lines (pancreatic cancer (SW1990) cells, breast cancer (MDA-MB-231 cells), and human lung cancer (Calu-6) cells), with hemoglobin content serving as a surrogate indicator of functional angiogenesis.